share_log

そーせいグループ:炎症性腸疾患(IBD)の治療薬候補であるEP4受容体作動薬HTL0033744の第1相臨床試験における最初の被験者への投与のお知らせ

Sosei Group: Notice of administration of the EP4 receptor agonist HTL0033744, which is a candidate drug for the treatment of inflammatory bowel disease (IBD), to subjects for the first phase 1 clinical trial

JPX ·  Mar 20 19:30
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more